Unicycive Therapeutics, Inc. announced a 1-for-10 reverse stock split effective June 18, 2025, reducing its outstanding shares from approximately 126.4 million to about 12.8 million. This move was approved by shareholders on June 9, 2025, and aims to adjust the company's capital structure without changing ownership percentages.